Akebia Therapeutics Initiates Phase 2 Basket Trial To Evaluate Safety, Efficacy, And Pharmacokinetics Of Ebribafusp For Treatment Of Rare Complement-Mediated Kidney Diseases
Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a Phase 2 basket trial to evaluate the
Akebia is testing a new medicine called Ebribafusp on patients with rare kidney diseases to see if it works safely and well. When a company starts testing a medicine on real people, it's a step forward—watch to see if the results come back good or bad.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.